Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolitesYukio Ago, Hitoshi Hashimoto, Rei Yokoyama et al.|Neuropharmacology|2022Cited by 24
Cyclic Peptides KS-133 and KS-487 Multifunctionalized Nanoparticles Enable Efficient Brain Targeting for Treating SchizophreniaKotaro Sakamoto, Eijiro Miyako, Ami Ono et al.|JACS Au|2024Cited by 11
Dimerisation of the VIP receptor VIPR2 is essential to its binding VIP and Gα<sub>i</sub> proteins, and to its functions in breast cancer cellsS Asano, Yukio Ago, Kairi Ozasa et al.|British Journal of Pharmacology|2025Cited by 3
Neuron-specific overexpression of human vasoactive intestinal peptide receptor 2 in mice causes cognitive dysfunction and abnormal dendritic morphology in the prefrontal cortexAmi Ono, Yukio Ago, Tatsunori Miyaoka et al.|Journal of Pharmacological Sciences|2025Cited by 1
An Improved Brain-Penetrating Nanoformulation of the VIPR2 Antagonist Peptide KS-133 for Treating Cognitive Impairment in SchizophreniaKotaro Sakamoto, Yukio Ago, Zihao Jin et al.|Biological and Pharmaceutical Bulletin|2026Cited by 0